학술논문
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)
Document Type
Article
Author
Source
In Annals of Oncology May 2016 27(5):880-886
Subject
Language
ISSN
0923-7534